RVTY

Revvity, Inc.

Technology
101.07 +0.68 +0.68% Market Closed
2026-06-03 • USD

Key Metrics

Market Cap 11.28B
EV —
Shares Out 111.56M
Revenue (ttm) 2.90B
Net Income 239.68M
Beta —
P/E 57.89
Forward P/E —
EPS (ttm) $2.08
P/S —
P/B 1.57
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 2.0%
ROE 3.25%
ROIC —
Gross Margin —
Oper. Margin 12.41%
Profit Margin 8.26%
Debt/Eq 0.47
LT Debt/Eq 26.82%
Quick Ratio —
Current Ratio 1.72
Book/sh 64.22
Cash/sh 7.69
Div Yield 0.28%
Div TTM $0.28
Payout Ratio 13.46%
SMA20 3.01%
SMA50 9.17%
SMA200 6.42%
Volume 1,152,600
Avg Volume 1.32M
Rel Volume —
Perf Week -3.33%
Perf Month 9.50%
Perf Quarter 4.66%
Perf Half Y 0.28%
Perf YTD 4.47%
Perf Year 11.68%
Perf 3Y -11.70%
Perf 5Y -27.27%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $0.0700
TTM Yield 0.28%
TTM Amount $0.28
Payout Ratio 13.46%
3-Yr Growth (CAGR) 0.00%
5-Yr Growth (CAGR) 0.00%

Last 12 Payouts

Period Ex-Date Amount / Share
Q1 2026 ~2026-04-05 $0.0700
Q1 2025 ~2025-12-28 $0.0700
Q3 2025 ~2025-09-28 $0.0700
Q2 2025 ~2025-06-29 $0.0700
Q1 2025 ~2025-03-30 $0.0700
Q1 2024 ~2024-12-29 $0.0700
Q3 2024 ~2024-09-29 $0.0700
Q2 2024 ~2024-06-30 $0.0700
Q1 2024 ~2024-03-31 $0.0700
Q1 2023 ~2023-12-31 $0.0700
Q3 2023 ~2023-10-01 $0.0700
Q2 2023 ~2023-07-02 $0.0700

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Revvity, Inc. is a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The company is revolutionizing what's possible in healthcare with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. Operating in more than 160 countries with approximately 11,000 employees, Revvity operates through two business segments: Life Sciences and Diagnostics. The Life Sciences segment provides comprehensive portfolio of technologies and products including reagents, instruments, and software that help researchers understand diseases and develop treatments across drug discovery and development. The Diagnostics segment includes immunodiagnostics, reproductive health, and life sciences solutions. Products and services span cell, gene, and protein research, high-content screening systems, in vivo optical imaging platforms, and cell analysis systems. The company partners with pharmaceutical, biotech, contract research organizations, academic and government institutions.

Name
Revvity, Inc.
Industry
Technology
CEO
Prahlad R. Singh · President and Chief Executive Officer
Employees
11,000 as of 2025-12-28
IPO Date
2012-02-22
Phone
(781) 663-6900
Address
77 4th Avenue, Waltham, MA 02451
Website
http://www.revvity.com

Key Executives

Name Title FY Pay
Michel Vounatsos Former Chief Executive Officer, Biogen Inc.; Board Member —
Alexis P. Michas Managing Partner, Juniper Investment Company, LLC; Non-Executive Chair —
Samuel R. Chapin Retired Executive Vice Chairman, Bank of America Merrill Lynch; Chair of Audit Committee —
Peter Barrett Partner, Atlas Venture; Chair of Compensation & Benefits Committee —
Prahlad R. Singh President and Chief Executive Officer —

Latest News